0 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Andrew Cheng
This company has no offices yet
Generate Biomedicines
3 followers
UNC Charlotte
6 followers
School District of Philadelphia
4 followers
Immunome
2 followers
Twist Bioscience
12 followers
JoVE (Journal of Visualized Experiments)
4 followers
Bloomberg Philanthropies
4 followers
Mission Bio
4 followers
Resilience
4 followers
Thermo Fisher Scientific
173 followers
Genentech
159 followers
Explore companies